Overview of Combantrin A

Quick Facts: Combantrin A (Albendazole)

Property	Description
Active ingredient	Albendazole
Form	Oral tablet (e.g., chewable), Oral suspension
Pharmacological class	Anthelmintic agent, Antiparasitic drug
General purpose	Elimination of parasitic worm infections
Origin / Status	Synthetic compound / Often Prescription-only (Rx)

What Type of Medicine is Combantrin A? (Identity and Classification)

Combantrin A is a brand name for a medicinal preparation containing the active ingredient Albendazole, which is classified as a broad-spectrum systemic anthelmintic agent. This drug belongs to the larger class of antiparasitic drugs and is designed primarily for the elimination of infections caused by various parasitic worms, known medically as helminthiasis. The drug is utilized for its efficacy against common intestinal nematodes. The systemic nature of this medicine means it is formulated to be absorbed into the bloodstream, allowing it to act against parasites residing throughout the body, not just those confined to the gastrointestinal tract.

What is Albendazole Made Of, and How Does it Function? (Composition and Mechanism Overview)

The therapeutic agent, Albendazole, is a synthetic compound derived from the benzimidazole carbamate chemical class. As a single active ingredient product, its composition is highly targeted. The drug works by specifically binding to beta-tubulin, which disrupts the parasite's vital internal structures. This action prevents the worm from absorbing essential nutrients like glucose, thereby starving the organism and halting the infection's development. Combantrin A is typically available as both an oral tablet (often a chewable tablet for easier ingestion) and an oral suspension, both designed for the oral route of administration (per os).

Regulatory References

Albendazole Mechanism of Action and Indications

What side effects are possible with Combantrin A?

Possible Side Effects and Safety Information

The safety profile of Combantrin A (Albendazole) details the adverse reactions and safety constraints documented in official regulatory labeling.

Frequency-Classified Adverse Reactions

Adverse effects are officially grouped by their documented frequency. Reactions classified as common in regulatory documents include headache, abdominal pain, nausea, and reversible alopecia (hair loss). Uncommon reactions often involve transient hepatic enzyme elevations and dizziness. Rare reports include severe blood disorders and serious skin conditions.

Systemic Safety Concerns

The most clinically significant adverse reactions involve the Blood and Lymphatic System and Hepatobiliary Disorders. Fatalities associated with severe bone marrow suppression, such as pancytopenia and agranulocytosis, have been documented in post-marketing reports. Rare instances of acute liver failure and severe hypersensitivity reactions like Stevens-Johnson syndrome are also listed.

Population-Specific Constraints

The official label includes specific restrictions for certain populations. The medicine is contraindicated during pregnancy due to the potential for fetal harm. Consequently, pregnancy testing and the use of effective contraception are regulatory requirements for women of reproductive potential during and after treatment. Patients with pre-existing hepatic impairment are considered at increased risk for toxicity.

Monitoring and Safety Patterns

The potential for systemic toxicity mandates frequent monitoring of liver enzyme levels and blood cell counts throughout the treatment period. Adverse effects, particularly those affecting the liver and blood, are more frequently observed during prolonged, high-dose regimens for systemic infections (e.g., hydatid disease) than during short courses for intestinal infections. This safety monitoring is a required regulatory element of the drug's use.

Overdose and Emergency Response

The official regulatory profile for Combantrin A (Albendazole) overdose details specific clinical manifestations and the potential for severe systemic toxicity. Overdose exposure may present with documented signs that include headache, vomiting, seizures, and extreme tiredness. Laboratory findings such as elevated liver enzymes and low levels of white blood cells (leukopenia) are also officially associated with high exposure.

The primary concern in a severe overdose is the potential for life-threatening outcomes involving the major physiological systems, specifically profound bone marrow suppression leading to pancytopenia and the occurrence of acute liver failure. Patients with underlying liver disease are identified in regulatory documents as a population at increased risk for these severe effects.

In the event of a suspected overdose, regulatory guidance requires seeking medical advice immediately. Emergency services must be contacted immediately if the affected individual experiences severe symptoms such as collapse, trouble breathing, seizure, or if they cannot be awakened. Management is restricted to supportive and symptomatic treatment, including the official use of gastric lavage and activated charcoal, as no specific antidote is currently documented.

Therapeutic Uses of Combantrin A

What Combantrin A Treats: Main Uses and Benefits

Combantrin A (Albendazole) is used for the therapeutic management of a broad spectrum of parasitic worm infections, known as helminthiasis. Its applications fall into distinct clinical and symptomatic domains. The medication is used to address severe infections caused by tapeworms, as well as several types of common intestinal worms.

Management of Systemic and Intestinal Symptoms

The medication is used for conditions including neurocysticercosis, hydatid disease, and various soil-transmitted helminths. This covers the medication’s role in managing deep-seated cysts in vital organs and common gut infections. Combantrin A is applied to manage these parasitic lesions, which helps address symptoms related to heightened neurological or organ stress, such as seizures and severe headaches. It also helps address symptoms of systemic imbalance and physical discomfort caused by intestinal worms.

Supportive symptom management may help patients cope more steadily with symptom fluctuations, contributing to improved comfort and assisting with maintaining functional stability.

Quick Fact: Relief for Systemic Imbalance

Combantrin A is commonly used to help with conditions where intestinal parasites lead to nutritional and systemic strain. This assists in managing symptoms linked to organ-specific functional stress, such as anemia and fatigue, thus contributing to easing the overall symptom load.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Combantrin A?

The population eligibility for using Combantrin A (Albendazole) is strictly defined by regulatory authorities based on contraindications, age, and underlying health status. The medicine is contraindicated and must not be used in patients with known hypersensitivity to albendazole, the benzimidazole class of compounds, or any component of the formulation.

Absolute Non-Eligibility

Population Group	Eligibility Status (Regulatory Wording)
Pregnancy	Contraindicated (Must not be used).
Hypersensitivity	Contraindicated (Known allergy to drug/class).

Restricted or Conditional Use

Use is conditional in several patient groups, requiring strict medical monitoring. Patients with active liver disease or signs of hepatic impairment must use the medicine with caution and require close monitoring of liver enzyme levels. Similarly, patients with a predisposition for bone marrow suppression (e.g., leukopenia) require continuous monitoring of blood cell counts.

Females of reproductive potential must be advised to use effective contraception during and for a specified period after treatment. Use is not recommended in children typically under 2 years of age due to limited safety data in this younger group. Experience with the medicine in the geriatric population is cited as limited.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Combantrin A (Albendazole) is defined by pharmacokinetic (PK) interactions that significantly alter the systemic exposure of the active metabolite, Albendazole sulfoxide. No co-administration drug combinations are formally listed as contraindicated in the core regulatory labels.

Exposure-Modifying Drug Interactions

Specific medicines are documented to increase the active metabolite’s systemic levels. The antihelminthic agent Praziquantel and the corticosteroid Dexamethasone increase the active metabolite’s plasma concentration ( C max) and AUC by approximately 50% and 56%, respectively. The H2 blocker Cimetidine is documented to increase active metabolite concentrations by approximately two-fold.

Conversely, regulatory documents highlight that co-administration with known hepatic enzyme inducers, such as certain anticonvulsants (e.g., Phenytoin, Carbamazepine), and Rifampicin, can decrease the systemic exposure of the active metabolite. This reduction poses a constraint as it may result in inadequate therapeutic effect. Additionally, Albendazole is documented to induce the CYP1A enzyme, necessitating caution for co-administered drugs like Theophylline.

Drug–Food and Population Notes

A necessary drug–food interaction requires the drug to be taken with a fat-containing meal for adequate systemic absorption and to achieve required exposure. Furthermore, patients with hepatic impairment are noted to be at an increased risk for drug-related adverse effects (bone marrow suppression) due to the drug’s metabolic pathway, requiring more frequent monitoring.

Mechanism of Action

The action of Combantrin A is highly specific to the parasitic organism, working through a defined two-step mechanism that targets the parasite's fundamental structural and metabolic systems.

Selective Targeting of Parasitic Microtubules

The mechanism begins with the active metabolite, albendazole sulfoxide, functioning as an inhibitor by preferentially binding to the mathbfbeta-tubulin found in the parasitic worm's cells. This binding specifically prevents the polymerization of tubulin dimers, thereby causing the disintegration of the cytoplasmic microtubules—the essential structural component (cytoskeleton) of the parasite. This process, which is essential for structural integrity and transport, is the molecular initiation of the drug's effect.

Collapse of Energy Metabolism

The damage to the microtubules causes an irreversible functional failure, primarily blocking the parasite's ability to absorb essential sugars like glucose across its intestinal and tegmental cells. This metabolic blockade rapidly depletes the worm's energy reserves (ATP and glycogen), resulting in a swift energy crash and the cessation of physiological activity. This metabolic collapse culminates in the cessation of the parasite's life-sustaining functions.

Dosage and Administration Information

How to use Combantrin A

The administration of Combantrin A (Albendazole) is defined by specific procedures for its systemic use. The drug is administered exclusively by the oral route and is available as a 200 mg tablet. The tablets may be crushed or chewed and swallowed with water to ease ingestion when necessary.

Official Dosing and Timing

Contextual Intake: The medicine is taken with food, specifically a meal, as this is required to optimize the absorption of the active ingredient into the bloodstream.

Frequency: For systemic infections, the total daily dose is administered in divided doses, twice daily (BID).

Dosing Regimen: Dosing is typically standardized at 400 mg per dose for individuals weighing 60 kg or more. For smaller individuals, the dose is calculated based on 15 mg/kg/day, administered in divided doses, with a maximum total daily dose of 800 mg.

Duration Pattern: Treatment follows distinct duration protocols. For certain infections, the course is continuous, such as 8 to 30 days. For other conditions, like Hydatid Disease, the medicine is used in a 28-day treatment cycle followed by a specified 14-day drug-free interval, which is then repeated.

Recent Clinical Evidence

Research evidence / Overview of studies for Combantrin A

Evidence for use in Systemic Cystic Infections (Neurocysticercosis)

Research into this condition was evaluated in study designs that included Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies monitored two main types of outcomes: radiological changes, which measured the number of remaining cysts or changes in lesion status visible on brain scans, and clinical patterns, which tracked the frequency and recurrence of seizures. Findings described patterns of change in lesion status in some patient groups. However, the evidence varied across studies for long-term clinical patterns, particularly seizure control in individuals presenting with multiple cysts. Long-term effects are not fully established regarding the sustained nature of seizure control.

Evidence for use in Common Intestinal Worms (Soil-Transmitted Helminths)

A large body of research, primarily consisting of Randomized Controlled Trials and meta-analyses, was studied for this category of infection. These trials focused on microbiological assessments: the Cure Rate (CR) and the Egg Reduction Rate (ERR). Research data show patterns related to consistently high microbiological outcome measurements reported for individuals infected with the Ascaris lumbricoides parasite and moderate measurements for hookworm infections. However, a low and decreasing microbiological outcome measurement was observed for individuals infected with Trichuriasis (T. trichiura).

Where Research is Inconsistent or Uncertain

Research highlights changes measured during the study period but points to areas where certainty remains low or findings were mixed. The evidence quality varies across studies, with the low reported microbiological outcome measurement for Trichuriasis being an area where research is ongoing. For systemic infections, comparative evidence is lacking in some contexts, and there is limited information for long-term outcomes that track sustained health and functional status over many years.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Combantrin A (FAQ)

Q: Is Combantrin A the same as the over-the-counter version I saw?

Official regulatory documents confirm that the active ingredient in Combantrin A, Albendazole, is classified as a prescription-only medicine (Rx) for human use in countries like the US, UK, and Canada. This classification indicates that the drug is dispensed under the supervision of a licensed healthcare provider. It is noted that other formulations, such as those intended for veterinary use, may be available without a prescription.

Q: How long can I expect the effects of Combantrin A to last?

The official product information describing how the medicine is processed in the body states that the active form of the drug, the metabolite known as albendazole sulfoxide, has a terminal elimination half-life that typically ranges from 8 to 12 hours. This refers to the time it takes for half of the drug to be eliminated from the bloodstream.

Q: Why is it sometimes recommended that the whole family take Combantrin A?

Recommendations for family-wide use often stem from official public health guidelines, rather than the drug's individual prescribing information. Organizations like the World Health Organization (WHO) may call for the use of the drug in mass drug administration programs. This is primarily for the control of highly transmissible intestinal worms, which involves treating community or family groups simultaneously to break the cycle of infection.

Q: Is Combantrin A safe to use if I am also taking vitamins, supplements, or herbal remedies?

Official regulatory documents indicate that patients are generally advised to disclose all products they are taking to their healthcare provider or pharmacist. This disclosure is important and typically includes all over-the-counter medicines, vitamins, minerals, and herbal products, as the potential for interactions is a known regulatory consideration.

Q: Are there any known interactions between Combantrin A and common pain relievers?

Official data confirms that the active ingredient, Albendazole, has a known potential for drug-drug interactions that can alter its concentration in the body. Specialized interaction databases, which rely on regulatory data, list common pain relievers like acetaminophen and aspirin as substances that may cause minor or moderate interactions.

Q: Can Combantrin A be used to prevent certain conditions, or is it only for treatment?

According to official indications, Combantrin A is primarily used for the treatment of established parasitic infections. However, research and clinical guidelines indicate that it is sometimes used in specific, supervised protocols for secondary prophylaxis. This aim is to prevent the recurrence of infections such as microsporidiosis in certain patient groups.

Q: What happens if I forget a dose of Combantrin A?

Patient education information found in regulatory sources typically describes the general approach to follow if a dose is missed. This guidance generally includes taking the dose as soon as remembered, unless it is close to the next scheduled dose, in which case the missed dose is skipped. Regulatory documents caution against taking two doses simultaneously to make up for a missed dose.

Q: What is the current safety classification of Combantrin A?

Regulatory bodies classify Combantrin A as a prescription-only medicine (POM/Rx) in many international jurisdictions. Additionally, official documents, such as the Australian TGA label, categorize the drug as Pregnancy Category D. This classification indicates that positive evidence of human fetal risk exists.

Q: Can someone who is vegetarian or vegan use Combantrin A?

The active ingredient, Albendazole, is a synthetic compound. However, the finished product contains excipients (non-active components) which are listed in official documents like the EU Summary of Product Characteristics (SmPC). This list of inactive ingredients is provided so that suitability for specific dietary needs, such as vegetarian or vegan requirements, can be determined.

Q: Are there restrictions on driving or operating machinery while using Combantrin A?

Official product information describes that the side effect dizziness has been reported with this medicine. Because of this, the regulatory label includes warnings that caution should be exercised regarding the ability to drive or operate machinery.

Q: Is it common for Combantrin A to cause changes in sleep patterns?

Official reports of adverse events documented during clinical studies and post-marketing surveillance list somnolence as a reported side effect. Somnolence is a medical term for drowsiness or unusual sleepiness, though the frequency with which this occurs can vary among individuals.

Q: What does the prescribing information say about using Combantrin A with alcohol?

Official patient education information regarding the use of the drug with alcohol states that it is generally unknown if drinking alcohol will directly affect the medicine's immediate function. However, the prescribing information notes that excessive or heavy drinking can compromise the body's general ability to fight the underlying infection.

Q: Is Combantrin A often used in combination with other prescription drugs?

Regulatory and clinical information confirms that Combantrin A is sometimes used alongside other specific prescription drugs. Examples include Praziquantel and Dexamethasone, which are known to interact by significantly altering the concentration of the active drug in the body. Because of this, close monitoring is often a part of the treatment protocol.

Q: What are the non-drug alternatives mentioned in relation to Combantrin A use?

Official global health documents and regulatory lists often frame the use of Albendazole in the context of other treatments. For instance, for certain tapeworm infections, the drug is sometimes listed as a chemical alternative to other antiparasitic medications like Praziquantel or Niclosamide.

Q: Does Combantrin A have any known effects on fertility?

Official product information states that the drug is contraindicated in women of childbearing potential who are not using effective contraception. This strong regulatory constraint is in place due to the known potential for fetal harm, which is the primary reproductive safety concern noted in the documents.

Q: Are there any special considerations for people with kidney issues using Combantrin A?

Official drug summaries indicate that specialized studies on the pharmacokinetics of the drug in patients with renal impairment (kidney issues) have not been formally performed. Despite this, the active metabolite is primarily eliminated through the liver, and the renal elimination is documented to be negligible.

How should Combantrin A be stored and disposed of?

The storage and disposal of Combantrin A (Albendazole) are governed by specific regulatory guidelines to maintain its efficacy and ensure environmental safety.

Storage Domain	Official Requirement
Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Excursions are permitted between 15 C and 30 C
Protection	Keep the product in a cool, dry place, protected from light, and away from excess heat [3.2]
Packaging	Keep the medicine in its original container and ensure the container is tightly closed [2.1]
Child Safety	Store the medication out of the sight and reach of children [2.1]
Disposal	Do not dispose of via household waste or wastewater. Discard unused or expired product through a drug take-back program or as directed by local regulations [2.2]

These conditions define the constraints for storing the anthelmintic agent. Disposal must follow a regulated protocol to prevent environmental contamination.

Combantrin A